fbpx

Screening for cardiovascular disease risk in people living with HIV

About HIV and cardiovascular risk

Did you know, people living with HIV have a 1.5- to 2-fold increased risk of developing cardiovascular disease?

 

Increased cardiovascular disease (CVD) risk in people living with HIV is the result of complex interactions between traditional risk factors, antiretroviral medicines (ART) mediated adverse effects and the chronic inflammation and immune activation associated with long-term HIV infection.

 

The Pharmaceutical Society of Australia has developed a Screening for cardiovascular disease risk in people living with HIV checklist that can be used to help you screen for risk factors for CVD in your patients living with HIV and guide you to educate and refer those at increased risk to see their doctor for a comprehensive clinical assessment.

 

The complete screening checklist contains an appendix with explanations of risk factors, risks associated with different ARTs. The checklist can be used in a variety of clinical settings. 

5460 HIV Hub Webtile
Webinar

Webinar Recording

Date: Tue, 30th Nov 21 

 

PSA launched the new screening checklist for pharmacists to use in practice with a webinar. This webinar recording will support pharmacists to implement a checklist to screen for cardiovascular disease (CVD) risk in people living with HIV, looking at traditional and HIV-specific risk factors to know when to refer patients at increased risk.

 

 

What is your role as a pharmacist?

Ensuring the most appropriate antiretroviral therapy is being used for your patients at increased risk of CVD events.

This webinar recording will provide education about the CVD risks associated with living with HIV and antiretroviral therapy. Listen to our experts discuss the evidence behind the ‘PSA Screening for cardiovascular disease risk in people living with HIV’ checklist and learn how to implement and use this in your practice to optimise patients health. This training will complement a suite of resources released by the PSA, including case scenarios in the Australian Pharmacist.